BioSpace News Archive

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with BMD.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer.

Promotes Rebecca Bradford to Vice President, Government Programs and Linda Johnson to Vice President of Licensing and Intellectual Property.

BioInvent International today resolved to elect Natalie Berner and Nanna Luneborg as new Board members.

NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the closing of a $12 million lead investment in the company’s Series D equity financing by Concord Innovation Fund II, LP.

BioCardia ® , Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Company’s CEO Peter Altman has been invited to participate at two upcoming therapeutic development symposia.

Citius Pharmaceuticals, Inc. today announced that the Company held a Type B pre-BLA meeting with the U.S. Food and Drug Administration (FDA) to discuss I/ONTAK (denileukin diftitox), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB).

Orion Biotechnology Canada Ltd and Peptilogics, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.